Is PAVMW or DIVO a better dividend investment in 2026?

PAVMW currently yields 6896.55% with a 5% 5-year dividend growth rate. DIVO yields 6.49% with 5% growth. The better choice depends on your goal: PAVMW offers higher current income.

What is the dividend yield difference between PAVMW and DIVO?

PAVMW has a forward dividend yield of 6896.55% ($2.00/share annually). DIVO yields 6.49% ($2.91/share annually). The yield gap is 6890.06 percentage points.

Home › Compare › PAVMW vs DIVO

PAVMW vs DIVO: Dividend Comparison 2026

PAVMW yields 6896.55% · DIVO yields 6.49%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 PAVMW wins by $1432605808592863.25M in total portfolio value

INVESTMENT

TIME HORIZON10 years

PAVMW

● Live price

6896.55%

Share price

$0.03

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$1432605808592863.25M

Annual income

$1,392,875,843,310,163,600,000.00

Full PAVMW calculator →

DIVO

● Live price

6.49%

Share price

$44.85

Annual div

$2.91

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$30.7K

Annual income

$981.68

Full DIVO calculator →

Portfolio growth — PAVMW vs DIVO

📍 PAVMW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	PAVMW	DIVO
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, PAVMW + DIVO cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

PAVMW pays

DIVO pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PAVMW

Annual income on $10K today (after 15% tax)

$586,206.90/yr

After 10yr DRIP, annual income (after tax)

$1,183,944,466,813,639,000,000.00/yr

DIVO

Annual income on $10K today (after 15% tax)

$552.00/yr

After 10yr DRIP, annual income (after tax)

$834.43/yr

At 15% tax rate, PAVMW beats the other by $1,183,944,466,813,639,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PAVMW + DIVO for your $10,000?

PAVMW: 50%DIVO: 50%

100% DIVO50/50100% PAVMW

Portfolio after 10yr

$716302904296431.63M

Annual income

$696,437,921,655,081,800,000.00/yr

Blended yield

97.23%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on PAVMW right now

PAVMW

Analyst Ratings

Buy

Consensus: Buy

Altman Z

-11.3

Piotroski

3/9

DIVO

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PAVMW buys

DIVO buys

No recent congressional trades found for PAVMW or DIVO in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricPAVMWDIVO

Forward yield	6896.55% ✓	6.49%
Annual dividend / share	$2.00	$2.91 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$1432605808592863.25M ✓	$30.7K
Annual income after 10y	$1,392,875,843,310,163,600,000.00 ✓	$981.68
Total dividends collected	$1429942114786334.00M ✓	$8.2K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: PAVMW vs DIVO ($10,000, DRIP)

Year	PAVMW Portfolio	PAVMW Income/yr	DIVO Portfolio	DIVO Income/yr	Gap
1← crossover	$700,355	$689,655.17	$11,349	$649.42	+$689.0K → PAVMW
2	$45,889,900	$45,140,520.30	$12,833	$688.83	+$45.88M → PAVMW
3	$2,813,379,172	$2,764,276,978.38	$14,459	$727.90	+$2813.36M → PAVMW
4	$161,393,449,836	$158,383,134,122.24	$16,238	$766.49	+$161393.43M → PAVMW
5	$8,664,159,276,546	$8,491,468,285,221.65	$18,179	$804.47	+$8664159.26M → PAVMW
6	$435,300,017,392,982	$426,029,366,967,078.00	$20,293	$841.71	+$435300017.37M → PAVMW
7	$20,469,824,923,231,620	$20,004,053,904,621,130.00	$22,591	$878.14	+$20469824923.21M → PAVMW
8	$901,046,035,934,427,400	$879,143,323,266,569,700.00	$25,087	$913.65	+$901046035934.40M → PAVMW
9	$37,130,808,675,420,410,000	$36,166,689,416,970,576,000.00	$27,791	$948.18	+$37130808675420.39M → PAVMW
10	$1,432,605,808,592,863,400,000	$1,392,875,843,310,163,600,000.00	$30,718	$981.68	+$1432605808592863.25M → PAVMW

PAVMW vs DIVO: Complete Analysis 2026

PAVMW — Stock

PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE). Its product pipeline also comprises EsoGuard, a molecular diagnostic esophageal DNA test; EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; PortIO, an implantable intraosseous vascular access device; and DisappEAR, a resorbable pediatric ear tube, as well as NextCath and Caldus. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is based in New York, New York.

Full PAVMW Calculator →

DIVO — ETF

DIVO is an ETF of high-quality large cap companies with a history of dividend and earnings growth, along with a tactical covered call* strategy on individual stocks. DIVO is strategically designed to offer high levels of total return on a risk-adjusted basis.

Full DIVO Calculator →

📬

Get this PAVMW vs DIVO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PAVMW vs SCHD PAVMW vs JEPI PAVMW vs O PAVMW vs KO PAVMW vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.